<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of Exclusive Patent License: Human Therapeutics for Fibrotic Disease</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of Exclusive Patent License: Human Therapeutics for Fibrotic Disease</h1>
    <p class="timestamp">Published: 2022-01-06 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Inversago Pharma, Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2022-00022</p>
    <p><strong>Publication Date:</strong> 2022-01-06</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/01/06/2022-00022/prospective-grant-of-exclusive-patent-license-human-therapeutics-for-fibrotic-disease">https://www.federalregister.gov/documents/2022/01/06/2022-00022/prospective-grant-of-exclusive-patent-license-human-therapeutics-for-fibrotic-disease</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-00022</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
